Birgit Burkhardt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2946381/publications.pdf

Version: 2024-02-01

134 papers	16,192 citations	50244 46 h-index	17580 121 g-index
142 all docs	142 docs citations	142 times ranked	26960 citing authors

#	Article	IF	Citations
1	Signatures of mutational processes in human cancer. Nature, 2013, 500, 415-421.	13.7	8,060
2	The landscape of genomic alterations across childhood cancers. Nature, 2018, 555, 321-327.	13.7	1,068
3	Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nature Genetics, 2012, 44, 1316-1320.	9.4	389
4	The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood, 2004, 105, 948-958.	0.6	304
5	Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood, 2011, 118, 139-147.	0.6	281
6	The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. British Journal of Haematology, 2005, 131, 39-49.	1.2	278
7	Next-generation personalised medicine for high-risk paediatric cancer patients â€“ The INFORM pilot study. European Journal of Cancer, 2016, 65, 91-101.	1.3	262
8	Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. Journal of Clinical Oncology, 2015, 33, 2963-2974.	0.8	202
9	Childhood cancer predisposition syndromesâ€”A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. American Journal of Medical Genetics, Part A, 2017, 173, 1017-1037.	0.7	200
10	A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood, 2014, 123, 1187-1198.	0.6	185
11	Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia. Journal of Clinical Oncology, 2010, 28, 3115-3121.	0.8	170
12	Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Mul̂nster) Multicenter Trial. Blood, 2006, 107, 4047-4052.	0.6	163
13	Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood, 2012, 119, 1882-1887.	0.6	163
14	Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. Journal of Clinical Oncology, 2021, 39, 295-307.	0.8	163
15	Poor Outcome for Children and Adolescents With Progressive Disease or Relapse of Lymphoblastic Lymphoma: A Report From the Berlin-Frankfurt-Muenster Group. Journal of Clinical Oncology, 2009, 27, 3363-3369.	0.8	147
16	Impact of Cranial Radiotherapy on Central Nervous System Prophylaxis in Children and Adolescents With Central Nervous Systemâ€“Negative Stage III or IV Lymphoblastic Lymphoma. Journal of Clinical Oncology, 2006, 24, 491-499.	0.8	146
17	Genomic profiling reveals different genetic aberrations in systemic ALKâ€positive and ALKâ€negative anaplastic large cell lymphomas. British Journal of Haematology, 2008, 140, 516-526.	1.2	145
18	Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALKâ€“positive anaplastic large-cell lymphoma. Blood, 2007, 110, 670-677.	0.6	130

#	Article	IF	Citations
19	Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents - a Berlin-Frankfurt-Munster group report. British Journal of Haematology, 2006, 133, 176-182.	1.2	119
20	DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control. Nature Genetics, 2015, 47, 1316-1325.	9.4	119
21	Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. Blood, 2008, 112, 1374-1381.	0.6	112
22	Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinaseâ€“positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood, 2010, 115, 3314-3319.	0.6	111
23	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discovery, 2021, 11, 2764-2779.	7.7	110
24	Pediatric follicular lymphoma - a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin's Lymphoma - Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials. Haematologica, 2010, 95, 253-259.	1.7	107
25	Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. Blood, 2013, 121, 3153-3160.	0.6	105
26	Relapsed or Refractory Anaplastic Large-Cell Lymphoma in Children and Adolescents After Berlin-Frankfurt-Muenster (BFM)â€“Type First-Line Therapy: A BFM-Group Study. Journal of Clinical Oncology, 2011, 29, 3065-3071.	0.8	101
27	Prevalence, Clinical Pattern, and Outcome of CNS Involvement in Childhood and Adolescent Non-Hodgkin's Lymphoma Differ by Non-Hodgkin's Lymphoma Subtype: A Berlin-Frankfurt-MÃ¼nster Group Report. Journal of Clinical Oncology, 2007, 25, 3915-3922.	0.8	99
28	Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. Nature Communications, 2019, 10, 1459.	5.8	99
29	Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica, 2011, 96, 262-268.	1.7	92
30	MINCR is a MYC-induced lncRNA able to modulate MYCâ€™s transcriptional network in Burkitt lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5261-70.	3.3	91
31	The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis. Blood, 2016, 127, 3281-3290.	0.6	83
32	Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. Nature Medicine, 2021, 27, 1806-1817.	15.2	79
33	Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis. Haematologica, 2010, 95, 2047-2055.	1.7	70
34	The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma. Blood, 2019, 133, 962-966.	0.6	69
35	Paediatric lymphoblastic Tâ€cell leukaemia and lymphoma: one or two diseases?. British Journal of Haematology, 2010, 149, 653-668.	1.2	68
36	Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a â€œwatch and waitâ€•strategy after complete resection. Annals of Hematology, 2013, 92, 1537-1541.	0.8	65

#	Article	IF	Citations
37	Recurrent loss of heterozygosity in 1p36 associated with TNFRSF14 mutations in IRF4 translocation negative pediatric follicular lymphomas. Haematologica, 2013, 98, 1237-1241.	1.7	65
38	Lymphoblastic lymphoma in children and adolescents: reviewÂof current challenges and future opportunities. British Journal of Haematology, 2019, 185, 1158-1170.	1.2	60
39	Sex differences in oncogenic mutational processes. Nature Communications, 2020, 11, 4330.	5.8	60
40	Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents. Haematologica, 2016, 101, 1581-1591.	1.7	58
41	Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. Leukemia and Lymphoma, 2008, 49, 451-461.	0.6	56
42	Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. Haematologica, 2017, 102, 2086-2096.	1.7	56
43	Diagnosis and Immunophenotype of 188 Pediatric Lymphoblastic Lymphomas Treated Within a Randomized Prospective Trial. American Journal of Surgical Pathology, 2011, 35, 836-844.	2.1	54
44	The genomic and transcriptional landscape of primary central nervous system lymphoma. Nature Communications, 2022, 13, 2558.	5.8	52
45	Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegenâ€breakage syndrome): a retrospective survey. British Journal of Haematology, 2011, 155, 468-476.	1.2	51
46	Recurrent RHOA mutations in pediatric <scp>B</scp>urkitt lymphoma treated according to the NHLâ€BFM protocols. Genes Chromosomes and Cancer, 2014, 53, 911-916.	1.5	51
47	Tumor Necrosis Factor and Lymphotoxin Alfa Genetic Polymorphisms and Outcome in Pediatric Patients With Non-Hodgkinâ€™s Lymphoma: Results From Berlin-Frankfurt-MÃ¼nster Trial NHL-BFM 95. Journal of Clinical Oncology, 2005, 23, 8414-8421.	0.8	50
48	IG-MYC+ neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas. Blood, 2018, 132, 2280-2285.	0.6	50
49	Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-MÃ¼nster protocols. Haematologica, 2017, 102, 1091-1098.	1.7	47
50	Experience with provisional WHOâ€entities large Bâ€cell lymphoma with IRF4â€rearrangement and Burkittâ€like lymphoma with 11q aberration in paediatric patients of the NHLâ€BFM group. British Journal of Haematology, 2020, 190, 753-763.	1.2	46
51	Immunreconstitution and Infectious Complications After Rituximab Treatment in Children and Adolescents: What Do We Know and What Can We Learn from Adults?. Cancers, 2015, 7, 305-328.	1.7	45
52	Current status and future directions of Tâ€lymphoblastic lymphoma in children and adolescents. British Journal of Haematology, 2016, 173, 545-559.	1.2	44
53	Alterations of microRNA and microRNA-regulated messenger RNA expression in germinal center B-cell lymphomas determined by integrative sequencing analysis. Haematologica, 2016, 101, 1380-1389.	1.7	43
54	Nonâ€anaplastic peripheral Tâ€cell lymphoma in children and adolescents â€“ a retrospective analysis of the <scp>NHL</scp>â€<scp>BFM</scp> study group. British Journal of Haematology, 2015, 168, 835-844.	1.2	42

#	Article	IF	Citations
55	ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. European Journal of Cancer, 2019, 110, 74-85.	1.3	39
56	Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial. Cancers, 2020, 12, 2747.	1.7	38
57	Sequential karyotyping in Burkitt lymphoma reveals a linear clonal evolution with increase in karyotype complexity and a high frequency of recurrent secondary aberrations. British Journal of Haematology, 2015, 170, 814-825.	1.2	36
58	Control of Multidrug-Resistant Pseudomonas aeruginosa in Allogeneic Hematopoietic Stem Cell Transplant Recipients by a Novel Bundle Including Remodeling of Sanitary and Water Supply Systems. Clinical Infectious Diseases, 2017, 65, 935-942.	2.9	34
59	Frequency and clinical relevance of DNA microsatellite alterations of the CDKN2A/B, ATM and p53 gene loci: a comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia. Haematologica, 2010, 95, 158-162.	1.7	32
60	Rare nonâ€Hodgkin lymphoma of childhood and adolescence: A consensus diagnostic and therapeutic approach to pediatricâ€type follicular lymphoma, marginal zone lymphoma, and nonanaplastic peripheral Tâ€cell lymphoma. Pediatric Blood and Cancer, 2020, 67, e28416.	0.8	32
61	Lymphoblastic Lymphoma in Childhood and Adolescence. Pediatric Hematology and Oncology, 2013, 30, 484-508.	0.3	31
62	Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance. Blood, 2021, 137, 2347-2359.	0.6	31
63	High resolution copy number analysis of IRF4 translocationâ€positive diffuse large Bâ€cell and follicular lymphomas. Genes Chromosomes and Cancer, 2013, 52, 150-155.	1.5	30
64	Whole exome sequencing hints at a unique mutational profile of paediatric Tâ€cell lymphoblastic lymphoma. British Journal of Haematology, 2015, 168, 308-313.	1.2	30
65	Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of <scp>EBMT</scp> group. American Journal of Hematology, 2020, 95, 809-816.	2.0	30
66	Primary central nervous system lymphoma in children and adolescents: low relapse rate after treatment according to Non-Hodgkin-Lymphoma Berlin-Frankfurt-Munster protocols for systemic lymphoma. Haematologica, 2014, 99, e238-e241.	1.7	29
67	The PCBP1 gene encoding poly(rc) binding protein i is recurrently mutated in <scp>B</scp>urkitt lymphoma. Genes Chromosomes and Cancer, 2015, 54, 555-564.	1.5	29
68	Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age. Nature Communications, 2022, 13, .	5.8	28
69	Favorable outcomes of hematopoietic stem cell transplantation in children and adolescents with Diamond-Blackfan anemia. Blood Advances, 2020, 4, 1760-1769.	2.5	27
70	Clinical characteristics and treatment outcome of infants with non-Hodgkin lymphoma. British Journal of Haematology, 2007, 139, 070916051811006-???.	1.2	26
71	Mature B-Cell Lymphoma and Leukemia in Children and Adolescentsâ€"Review of Standard Chemotherapy Regimen and Perspectives. Pediatric Hematology and Oncology, 2013, 30, 465-483.	0.3	26
72	Neurotoxic side effects in children with refractory or relapsed Tâ€cell malignancies treated with nelarabine based therapy. British Journal of Haematology, 2017, 179, 272-283.	1.2	25

#	Article	IF	Citations
73	Progressive or Relapsed Burkitt Lymphoma or Leukemia in Children and Adolescents after BFM-type First-line Therapy. Blood, 2020, 135, 1124-1132.	0.6	25
74	Cryptic insertion of MYC exons 2 and 3 into the immunoglobulin heavy chain locus detected by whole genome sequencing in a case of â€œMYC-negativeâ€•Burkitt lymphoma. Haematologica, 2020, 105, e202-e205.	1.7	24
75	Clinical and pathological features of Burkitt lymphoma showing expression of <scp>BCL</scp>2 â€“ an analysis including gene expression in formalinâ€fixed paraffinâ€embedded tissue. British Journal of Haematology, 2015, 171, 501-508.	1.2	23
76	Cellâ€ofâ€origin classification by gene expression and MYCâ€rearrangements in diffuse large Bâ€cell lymphoma of children and adolescents. British Journal of Haematology, 2017, 179, 116-119.	1.2	23
77	Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations. Cancers, 2021, 13, 2075.	1.7	23
78	MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma. Cancer Research, 2019, 79, 3125-3138.	0.4	19
79	Hematopoietic stem cell transplantation for children with acute myeloid leukemiaâ€”results of the AML SCT-BFM 2007 trial. Leukemia, 2020, 34, 613-624.	3.3	19
80	The CBFA2T3/ACSF3 locus is recurrently involved in IGH chromosomal translocation t(14;16)(q32;q24) in pediatric Bâ€cell lymphoma with germinal center phenotype. Genes Chromosomes and Cancer, 2012, 51, 338-343.	1.5	18
81	Children and adolescents with marginal zone lymphoma have an excellent prognosis with limited chemotherapy or a watchâ€andâ€wait strategy after complete resection. Pediatric Blood and Cancer, 2018, 65, e26932.	0.8	18
82	Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC. Leukemia and Lymphoma, 2018, 59, 1213-1221.	0.6	18
83	Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma. Haematologica, 2019, 104, e17-e20.	1.7	18
84	Treosulfanâ€“fludarabineâ€“thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies. Bone Marrow Transplantation, 2020, 55, 1996-2007.	1.3	18
85	Epsteinâ€“Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features. British Journal of Haematology, 2022, 196, 681-689.	1.2	18
86	Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents. Blood Advances, 2019, 3, 4291-4297.	2.5	17
87	Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia. Annals of Hematology, 2016, 95, 1503-1512.	0.8	16
88	Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma. Leukemia, 2021, 35, 639-643.	3.3	16
89	Epidemiology, utilisation of healthcare resources and outcome of invasive fungal diseases following paediatric allogeneic haematopoietic stem cell transplantation. Mycoses, 2020, 63, 172-180.	1.8	15
90	Novel oncogene amplifications in tumors from a family with Liâ€“Fraumeni syndrome. Genes Chromosomes and Cancer, 2009, 48, 558-568.	1.5	13

#	Article	IF	Citations
91	Excellent outcome with limited treatment in paediatric patients with marginal zone lymphoma. British Journal of Haematology, 2018, 182, 735-739.	1.2	12
92	Primary postâ€transplant lymphoproliferative disorder of the central nervous system: characteristics, management and outcome in 25 paediatric patients. British Journal of Haematology, 2021, 193, 1178-1184.	1.2	11
93	Second malignant neoplasms after treatment of non-Hodgkinâ€™s lymphomaâ€”a retrospective multinational study of 189 children and adolescents. Leukemia, 2021, 35, 534-549.	3.3	10
94	Cell cycle regulatory molecular profiles of pediatric T-cell lymphoblastic leukemia and lymphoma. Leukemia and Lymphoma, 2012, 53, 557-568.	0.6	9
95	Childhood acute lymphoblastic leukemia-associated risk-lociIKZF1, ARID5BandCEBPEand risk of pediatric non-Hodgkin lymphoma: a report from the Berlinâ€“Frankfurtâ€“MÃ¼nster Study Group. Leukemia and Lymphoma, 2015, 56, 814-816.	0.6	9
96	Epidemiology and management burden of invasive fungal infections after autologous hematopoietic stem cell transplantation: 10â€year experience at a European Pediatric Cancer Center. Mycoses, 2019, 62, 954-960.	1.8	9
97	Solid organ transplantation after hematopoietic stem cell transplantation in childhood: A multicentric retrospective survey. American Journal of Transplantation, 2019, 19, 1798-1805.	2.6	9
98	Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy. Leukemia, 2020, 34, 2271-2275.	3.3	9
99	Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning. Pediatric Blood and Cancer, 2020, 67, e28523.	0.8	8
100	Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma. Haematologica, 2021, 106, 3232-3235.	1.7	8
101	Secondary Neoplasms Subsequent to Berlin-Frankfurt-Muenster (BFM) Therapy of Non-Hodgkin Lymphoma of Childhood: Significantly Higher Risk for Patients with Lymphoblastic Lymphoma Compared to Other NHL-Subtypes.. Blood, 2005, 106, 232-232.	0.6	8
102	Treatment of Adolescents with Aggressive B-Cell Malignancies: The Pediatric Experience. Current Hematologic Malignancy Reports, 2013, 8, 226-235.	1.2	7
103	Nonâ€leukemic pediatric mixed phenotype acute leukemia/lymphoma: Genomic characterization and clinical outcome in a prospective trial for pediatric lymphoblastic lymphoma. Genes Chromosomes and Cancer, 2019, 58, 365-372.	1.5	6
104	Molecular features of nonâ€anaplastic peripheral Tâ€cell lymphoma in children and adolescents. Pediatric Blood and Cancer, 2021, 68, e29285.	0.8	6
105	Complex MLL rearrangement in nonâ€infiltrated bone marrow in an infant with stage II precursor Bâ€lymphoblastic lymphoma. European Journal of Haematology, 2014, 93, 349-353.	1.1	5
106	Treatment and outcome of IG-MYC+ neoplasms with precursor B-cell phenotype in childhood and adolescence. Leukemia, 2020, 34, 942-946.	3.3	5
107	CopyDetective: Detection thresholdâ€“aware copy number variant calling in whole-exome sequencing data. GigaScience, 2020, 9, .	3.3	5
108	Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study group. Haematologica, 2021, 106, 1390-1400.	1.7	5

#	Article	IF	Citations
109	Other (Non-CNS/Testicular) Extramedullary Localizations of Childhood Relapsed Acute Lymphoblastic Leukemia and Lymphoblastic Lymphomaâ€"A Report from the ALL-REZ Study Group. Journal of Clinical Medicine, 2021, 10, 5292.	1.0	5
110	Multiplex ligation-dependent probe amplification validates LOH6q analyses and enhances insight into chromosome 6q aberrations in pediatric T-cell lymphoblastic leukemia and lymphoma. Leukemia and Lymphoma, 2015, 56, 1884-1887.	0.6	4
111	Mature aggressive B-cell lymphoma across age groups â€“ molecular advances and therapeutic implications. Expert Review of Hematology, 2017, 10, 123-135.	1.0	4
112	Durable control of hepatitis C through interferonâ€free antiviral combination therapy immediately prior to allogeneic haematopoietic stem cell transplantation. Journal of Viral Hepatitis, 2019, 26, 454-458.	1.0	3
113	Patient parameters and response after administration of rituximab in pediatric mature Bâ€cell nonâ€Hodgkin lymphoma. Pediatric Blood and Cancer, 2022, 69, e29514.	0.8	3
114	Immunohistochemical detection of inhibitor of DNA binding 3 mutational variants in mature aggressive B-cell lymphoma. Haematologica, 2016, 101, e259-e261.	1.7	2
115	Malignant Lymphomas in Childhood. , 2018, , 1330-1342.e5.		2
116	Relapsed or Refractory Burkitt Lymphoma in Children and Adolescents after BFM-Type First-Line Therapy - a BFM Group Report. Blood, 2014, 124, 1738-1738.	0.6	2
117	Design of a targeted nextâ€generation DNA sequencing panel for pediatric Tâ€cell lymphoblastic lymphoma to unravel biology and optimize treatment. Genes Chromosomes and Cancer, 2022, 61, 459-470.	1.5	2
118	XI. Management of paediatric and adult nonâ€Hodgkin lymphoma: what lessons can each teach the other?. Hematological Oncology, 2015, 33, 62-66.	0.8	1
119	CD38 is not expressed in pediatric ALKâ€positive anaplastic large cell lymphoma. Pediatric Blood and Cancer, 2019, 66, e27541.	0.8	1
120	Pediatric T-Cell Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma: Differences in the Common Deleted Region and the Prognostic Impact of Chromosome 6q Deletions.. Blood, 2006, 108, 294-294.	0.6	1
121	Proposal of a Genetic Classifier for Risk Group Stratification in Pediatric T-Cell Lymphoblastic Lymphoma Reveals Significant Differences to T-Cell Lymphoblastic Leukemia. Blood, 2014, 124, 2398-2398.	0.6	1
122	Clinical Heterogeneity in RUNX1-Associated Familial Myelodysplastic Syndrome - Report of Two Novel Pedigrees with Childhoodleukemia. Blood, 2016, 128, 5509-5509.	0.6	1
123	The EHA Research Roadmap: Malignant Lymphoid Diseases. HemaSphere, 2022, 6, e726.	1.2	1
124	Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia. Leukemia, 0, , .	3.3	1
125	Lymphoblastic Lymphoma. , 2019, , 153-164.		0
126	Marginal Zone Lymphoma. , 2019, , 221-227.		0

#	Article	IF	Citations
127	Circulating Antibodies to ALK Inversely Correlat with Relapse Risk and Circulating Tumor Cells in Children and Adolescents with ALK-Positive Anaplastic Large Cell Lymphoma. Blood, 2008, 112, 2831-2831.	0.6	0
128	Poor Outcome for Children and Adolescents with Progressive Disease or Relapse of Lymphoblastic Lymphoma - a Report of the BFM Group. Blood, 2008, 112, 3589-3589.	0.6	0
129	Prognostic Impact of Fc Gamma-Receptor Polymorphisms and Efficacy of Rituximab in Children and Adolescents with Mature Aggressive B-NHL. Blood, 2012, 120, 1547-1547.	0.6	0
130	Abstract 3092: PTEN mutations correlate with relapse risk in pediatric T-cell lymphoblastic lymphoma patients: Validation of whole exome sequencing results. , 2014, , .		0
131	New Insights into Potential Driver Mutations in Pediatric Burkitt Lymphoma. Blood, 2014, 124, 2980-2980.	0.6	0
132	Stem Cell Transplantation for Pediatric Patients with Non-Anaplastic Peripheral T-Cell Lymphoma on Behalf of the EBMT-Pediatric Diseases Working Party. Blood, 2018, 132, 5787-5787.	0.6	0
133	Prospective Clinical Phase II Results on Treosulfan-Based Conditioning Treatment of 70 Paediatric Patients with Haematological Malignancies. Blood, 2018, 132, 3354-3354.	0.6	0
134	Aggressive Lymphoma in Children and Adolescents. Mechanical Engineering Series, 2019, , 245-282.	0.1	0